What this pack is
ALTACE is the brand name in this record; ramipril is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
ALTACEGeneric nameramipril
How this medicine works
The current label explains that ramipril is hydrolysed by esterases to the active metabolite ramiprilat. ACE inhibition reduces formation of angiotensin II and lowers aldosterone secretion, helping explain why blood pressure, kidney function, potassium, volume status and interactions need review together; the mechanism cannot predict individual response or determine an amount.
Read source: United States ↗Current regulatory record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- ALTACE
- Generic name
- ramipril
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v29 (effective 19 May 2026)
Ramipril 1.25 mg per capsule; NDC 61570-110-01; 100-capsule bottle
- Product code
- NDC 61570-110-01
- Form and route
- ALTACE ramipril hard gelatin oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- ramipril
- 1.25 mglabelled amount per capsule; not an individual's capsule count, frequency or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- yellow · capsule-shaped; no score · imprint Altace 1 25 mg MPNot scored in this labelled presentation
United States label · DailyMed SPL v29 (effective 19 May 2026)
Ramipril 2.5 mg per capsule; NDC 61570-111-01; 100-capsule bottle
- Product code
- NDC 61570-111-01
- Form and route
- ALTACE ramipril hard gelatin oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- ramipril
- 2.5 mglabelled amount per capsule; not an individual's capsule count, frequency or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- orange · capsule-shaped; no score · imprint Altace 2 5 mg MPNot scored in this labelled presentation
United States label · DailyMed SPL v29 (effective 19 May 2026)
Ramipril 5 mg per capsule; NDC 61570-112-01; 100-capsule bottle
- Product code
- NDC 61570-112-01
- Form and route
- ALTACE ramipril hard gelatin oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- ramipril
- 5 mglabelled amount per capsule; not an individual's capsule count, frequency or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- red · capsule-shaped; no score · imprint Altace 5 mg MPNot scored in this labelled presentation
United States label · DailyMed SPL v29 (effective 19 May 2026)
Ramipril 10 mg per capsule; NDC 61570-120-01; 100-capsule bottle
- Product code
- NDC 61570-120-01
- Form and route
- ALTACE ramipril hard gelatin oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- ramipril
- 10 mglabelled amount per capsule; not an individual's capsule count, frequency or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- blue · capsule-shaped; no score · imprint Altace 10 mg MPNot scored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ALTACE/ramipril label reading: check milligrams per capsule, then the exact capsule-opening boundary
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current U.S. label lists ALTACE as hard gelatin ramipril capsules in 1.25, 2.5, 5 and 10 mg strengths. mg is the labelled amount per capsule, not a personal capsule count generated by the site. A capsule has no score to split in half. The label has a product-specific opening-and-mixing option for exact ALTACE capsules, which does not establish that another ramipril or another capsule may be opened.
- Check ALTACE, ramipril, oral capsule, 1.25/2.5/5/10 mg, NDC, colour, imprint and target market together. Do not treat a ramipril tablet, generic capsule, enalapril, captopril, lisinopril or an ARB as the same product.
- 1.25, 2.5, 5 and 10 mg each state the labelled amount per capsule. Individual use also depends on the prescription, indication, blood pressure, kidney function, potassium, age, volume status and complete medicine list; the site cannot convert a strength into a capsule count or daily total.
- The current label generally says to swallow the capsule whole and also permits the exact ALTACE capsule to be opened, with all contents mixed into about 4 oz of applesauce or 120 mL of water or apple juice and consumed in full. This only explains the source label. Swallowing difficulty, feeding tubes, storage, another brand or paediatric use still require pharmacist review, and capsule contents must not be divided by eye.
- Place diuretics, potassium supplements, potassium-containing salt substitutes, NSAIDs such as ibuprofen/naproxen, lithium, other ACE inhibitors, ARBs, aliskiren and sacubitril/valsartan on one list for review. Do not self-combine, separate, alternate, stop or substitute.
- Swelling of the face, lips, tongue or throat, breathing or swallowing difficulty, fainting or another severe acute problem requires immediate local emergency help; do not wait for a website decision. Pregnancy or possible pregnancy also requires prompt contact with the prescribing team because the U.S. label carries a boxed warning for fetal toxicity.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ALTACE ramipril public label (Pfizer; SPL v29, effective 19 May 2026) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-28FDA Drugs@FDA: current ALTACE (ramipril) NDA 019901 application record ↗Current regulatory record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about ALTACE (ramipril). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
ALTACE is the brand in this record and ramipril is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. ALTACE ramipril public label (Pfizer; SPL v29, effective 19 May 2026) ↗Current regulatory record · reviewed 2026-08-28
- FDA Drugs@FDA: current ALTACE (ramipril) NDA 019901 application record ↗Current regulatory record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How ramipril works: a prodrug converted to ramiprilat, then ACE inhibition
- Sharing the ACE-inhibitor class does not make ramipril self-combinable, milligram-convertible or alternate-day interchangeable with enalapril, captopril or lisinopril; ARBs and sacubitril/valsartan also require exact medicine- and current-label review.
- Dry cough, dizziness, weakness, urine change or an abnormal test cannot be attributed from mechanism alone and is not a reason to self-stop, redose or change to another blood-pressure medicine; take the actual pack and complete medicine list to a professional.
- Mechanism terms do not replace clinical review of blood pressure, kidney function, electrolytes, pregnancy status and the complete medicine list. Face/tongue/throat swelling, breathing difficulty, fainting or another severe acute problem requires immediate local emergency support.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA Drugs@FDA: current ALTACE (ramipril) NDA 019901 application record ↗Current regulatory record · reviewed 2026-08-28
- DailyMed (NLM): current U.S. ALTACE ramipril public label (Pfizer; SPL v29, effective 19 May 2026) ↗Current regulatory record · reviewed 2026-08-28
SOURCE-TRACEABLE ARCHIVE
ALTACEramipril
This page includes an exact current U.S. public-label package panel for ALTACE, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. marketing record for ALTACE capsules
The current DailyMed NDA brand label lists ALTACE's initial U.S. approval as 1991 and links NDA019901 to a marketing start date of 28 Jan 1991 in its product data. This historical node establishes U.S. product history only and does not automatically establish another market's brand, approval, supply or interchangeability.
DailyMed (NLM): current U.S. ALTACE ramipril public label (initial approval and product data) ↗Current U.S. ALTACE SPL v29 effective
The current DailyMed label lists ALTACE, NDA019901, Pfizer, hard gelatin 1.25/2.5/5/10 mg capsules, exact NDCs, colours, imprints and four bottle display panels, and updates the angioedema warning. The page keeps label version and historical NDC marketing dates separate from live stock and purchase.
DailyMed (NLM): current U.S. ALTACE ramipril public label (SPL v29) ↗
MARKET SCOPE
Market-record boundary
United States
Current NDA brand label and four 100-capsule bottle panels linked; live supply not establishedThe dossier separately records NDC, colour, ALTACE/MP imprint, no-score status and source for 1.25, 2.5, 5 and 10 mg. DailyMed product data also lists historical marketing end dates for individual NDCs, so a current label is not described as current stock. The record does not authenticate, sell or decide an individual's capsule count, frequency, capsule opening, stopping, co-use or switching.
Mainland China, the EU, Japan and other markets
Current regulatory product record not establishedNo local trade name, approval, package, supply, originator/reference relationship or interchangeability is inferred from the U.S. ALTACE name, NDA, shared generic name, NDC, milligram value, capsule colour, imprint or package image; each product requires current local regulatory review.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Are ALTACE, ramipril, enalapril and captopril the same thing?
ALTACE is the trade name of the cited U.S. ramipril product, while ramipril is the generic name; enalapril and captopril are different ingredients. Even though all are ACE inhibitors, that does not support self-combining, alternating, milligram conversion or substitution. Have a pharmacist or prescriber review the actual packs, prescription and complete medicine list.
ALTACE is a capsule; can it be opened or divided in half?
The current U.S. label for the exact ALTACE capsule describes swallowing whole or opening it and mixing all contents with a specified small amount of food or liquid for complete consumption. That does not permit division by eye and does not apply automatically to another ramipril capsule, brand, dosage form, feeding tube or individual context. Check the exact product and prescription, then confirm with a pharmacist.
Can ALTACE be used with valsartan, sacubitril/valsartan, a diuretic, ibuprofen or potassium?
The site cannot decide individual co-use. These names signal that all prescriptions, OTC pain medicines, supplements, potassium-containing salt substitutes, blood pressure, kidney function and electrolytes need item-by-item review by a pharmacist or prescriber; do not self-combine, separate, alternate by day, stop or substitute.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.